Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Area of Science:

• Virology
• Pharmacology
• Drug Development

Background:

• Molnupiravir is a prodrug whose active metabolite, β-D-N4-hydroxycytidine, is an effective antiviral agent against COVID-19.
• The drug targets the RNA-dependent RNA polymerase (RdRp) enzyme, crucial for viral genome replication.

Purpose of the Study:

• To review the efficacy of molnupiravir and its metabolite against SARS-CoV-2 variants of concern.
• To elucidate the molecular mechanisms and interactions of molnupiravir using computational methods.
• To assess the safety and tolerability of molnupiravir in patients with comorbidities.

Main Methods:

• Literature review of molnupiravir's antiviral activity.
• Molecular docking and dynamics simulations to analyze drug-target interactions.
• Analysis of clinical data regarding safety and tolerability in patients with comorbidities.

Main Results:

• Molnupiravir demonstrates efficacy against various SARS-CoV-2 variants, including delta and omicron.
• Molecular modeling provides insights into the mechanism of action, highlighting how it induces errors in viral RNA replication.
• The drug is generally safe and well-tolerated in patients with underlying health conditions.

Conclusions:

• Molnupiravir is a valuable therapeutic option for COVID-19, effective against emerging variants.
• Understanding its molecular interactions aids in predicting and potentially overcoming resistance.
• Its favorable safety profile supports its use in diverse patient populations.